The dissatisfied delivery efficiency of drugs to lungs and other metastatic sites limit the corresponding therapeutic efficacy. Here this group reports an inhalable surfactant-based nanoliposome system to co-deliver Osimertinib and DNA plasmid which is capable of fusing into pulmonary surfactant, penetrating through physiological barriers and targeted accumulating in lung tissues.
- Xianglei Fu
- Yanbin Shi
- Guimei Lin
